

Vilazodone (Viibryd) is an antidepressant used for major depression. Learn about its uses, dosage, cost, side effects, and what makes it different in 2026.
Vilazodone (sold under the brand name Viibryd) is a prescription antidepressant that works differently from traditional SSRIs. If your doctor has mentioned Vilazodone as a treatment option, or if you're researching it on your own, this guide covers everything you need to know — from what it is and how it's used, to how much it costs and who shouldn't take it.
Vilazodone hydrochloride is a prescription antidepressant that belongs to a class called serotonin partial agonist-reuptake inhibitors, or SPARIs. It's also sometimes classified as a serotonin modulator or miscellaneous antidepressant.
Key facts about Vilazodone:
What makes Vilazodone unique is its dual mechanism. Unlike standard SSRIs that only block serotonin reuptake, Vilazodone also partially activates the serotonin 5-HT1A receptor. This combination may offer certain advantages, including a potentially faster onset of action and fewer sexual side effects. To learn more about how this works, read our guide on how Vilazodone works.
Vilazodone is FDA-approved for one condition:
However, doctors sometimes prescribe Vilazodone off-label for other conditions, including:
Off-label use means the drug is prescribed for a condition not specifically approved by the FDA, but where clinical evidence or a doctor's judgment suggests it may help.
Vilazodone comes as an oral tablet in three strengths: 10 mg, 20 mg, and 40 mg.
The standard dosing schedule is:
Important dosing rules:
If your doctor prescribes a strong CYP3A4 inhibitor (like Ketoconazole or Clarithromycin) alongside Vilazodone, the dose may be reduced to 20 mg daily. Conversely, if you're taking a strong CYP3A4 inducer (like Carbamazepine or Rifampin), the dose may need to increase. See our full drug interactions guide for details.
Vilazodone is not safe for everyone. Do not take Vilazodone if you:
Use with caution if you:
Vilazodone is not approved for patients under 18.
For a detailed overview of side effects, including what to watch for and when to call your doctor, read our Vilazodone side effects guide.
The cost of Vilazodone varies significantly depending on whether you use insurance, a discount coupon, or pay the full retail price:
Insurance coverage: Generic Vilazodone is covered by most commercial insurance plans and Medicare Part D, usually at a lower copay tier. Brand-name Viibryd is typically Tier 4 (specialty/non-preferred) and may require prior authorization or step therapy (trying a generic SSRI first).
Savings programs: AbbVie offers a Viibryd Savings Card for commercially insured patients — eligible patients may pay as little as $0 per fill. For uninsured patients, the AbbVie Patient Assistance Foundation provides Viibryd at no cost to qualifying individuals who meet income requirements.
For more ways to reduce your cost, check out our guide on how to save money on Vilazodone.
Vilazodone is a unique antidepressant that offers an alternative to traditional SSRIs for adults with major depressive disorder. Its dual mechanism — combining serotonin reuptake inhibition with partial 5-HT1A agonism — sets it apart from older antidepressants and may offer benefits for patients who haven't found relief with other medications or who experienced unwanted side effects.
If you and your doctor decide that Vilazodone is right for you, use Medfinder to find a pharmacy with it in stock near you, and explore our other guides for help with finding a prescriber and saving money on your prescription.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.